Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells.
Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has n...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/86b597f6dd8c41bea39c1cea84b3d20c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:86b597f6dd8c41bea39c1cea84b3d20c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:86b597f6dd8c41bea39c1cea84b3d20c2021-11-18T07:42:39ZBleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells.1932-620310.1371/journal.pone.0065181https://doaj.org/article/86b597f6dd8c41bea39c1cea84b3d20c2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23762310/?tool=EBIhttps://doaj.org/toc/1932-6203Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has not been evaluated. We make here the observation that BLM induces immunogenic cell death. In particular, BLM is able to induce ROS-mediated reticulum stress and autophagy, which result in the surface exposure of chaperones, including calreticulin and ERp57, and liberation of HMBG1 and ATP. BLM induces anti-tumor immunity which relies on calreticulin, CD8(+) T cells and interferon-γ. We also find that, in addition to its capacity to trigger immunogenic cell death, BLM induces expansion of Foxp3+ regulatory T (Treg) cells via its capacity to induce transforming growth factor beta (TGFβ) secretion by tumor cells. Accordingly, Treg cells or TGFβ depletion dramatically potentiates the antitumor effect of BLM. We conclude that BLM induces both anti-tumor CD8(+) T cell response and a counteracting Treg proliferation. In the future, TGFβ or Treg inhibition during BLM treatment could greatly enhance BLM anti-tumor efficacy.Hélène BugautMélanie BruchardHélène BergerValentin DerangèreLudivine OdoulRomain EuvrardSylvain LadoireFanny ChalminFrédérique VégranCédric RébéLionel ApetohFrançois GhiringhelliGrégoire MignotPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 6, p e65181 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Hélène Bugaut Mélanie Bruchard Hélène Berger Valentin Derangère Ludivine Odoul Romain Euvrard Sylvain Ladoire Fanny Chalmin Frédérique Végran Cédric Rébé Lionel Apetoh François Ghiringhelli Grégoire Mignot Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. |
| description |
Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has not been evaluated. We make here the observation that BLM induces immunogenic cell death. In particular, BLM is able to induce ROS-mediated reticulum stress and autophagy, which result in the surface exposure of chaperones, including calreticulin and ERp57, and liberation of HMBG1 and ATP. BLM induces anti-tumor immunity which relies on calreticulin, CD8(+) T cells and interferon-γ. We also find that, in addition to its capacity to trigger immunogenic cell death, BLM induces expansion of Foxp3+ regulatory T (Treg) cells via its capacity to induce transforming growth factor beta (TGFβ) secretion by tumor cells. Accordingly, Treg cells or TGFβ depletion dramatically potentiates the antitumor effect of BLM. We conclude that BLM induces both anti-tumor CD8(+) T cell response and a counteracting Treg proliferation. In the future, TGFβ or Treg inhibition during BLM treatment could greatly enhance BLM anti-tumor efficacy. |
| format |
article |
| author |
Hélène Bugaut Mélanie Bruchard Hélène Berger Valentin Derangère Ludivine Odoul Romain Euvrard Sylvain Ladoire Fanny Chalmin Frédérique Végran Cédric Rébé Lionel Apetoh François Ghiringhelli Grégoire Mignot |
| author_facet |
Hélène Bugaut Mélanie Bruchard Hélène Berger Valentin Derangère Ludivine Odoul Romain Euvrard Sylvain Ladoire Fanny Chalmin Frédérique Végran Cédric Rébé Lionel Apetoh François Ghiringhelli Grégoire Mignot |
| author_sort |
Hélène Bugaut |
| title |
Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. |
| title_short |
Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. |
| title_full |
Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. |
| title_fullStr |
Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. |
| title_full_unstemmed |
Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. |
| title_sort |
bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory t cells. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/86b597f6dd8c41bea39c1cea84b3d20c |
| work_keys_str_mv |
AT helenebugaut bleomycinexertsambivalentantitumorimmuneeffectbytriggeringbothimmunogeniccelldeathandproliferationofregulatorytcells AT melaniebruchard bleomycinexertsambivalentantitumorimmuneeffectbytriggeringbothimmunogeniccelldeathandproliferationofregulatorytcells AT heleneberger bleomycinexertsambivalentantitumorimmuneeffectbytriggeringbothimmunogeniccelldeathandproliferationofregulatorytcells AT valentinderangere bleomycinexertsambivalentantitumorimmuneeffectbytriggeringbothimmunogeniccelldeathandproliferationofregulatorytcells AT ludivineodoul bleomycinexertsambivalentantitumorimmuneeffectbytriggeringbothimmunogeniccelldeathandproliferationofregulatorytcells AT romaineuvrard bleomycinexertsambivalentantitumorimmuneeffectbytriggeringbothimmunogeniccelldeathandproliferationofregulatorytcells AT sylvainladoire bleomycinexertsambivalentantitumorimmuneeffectbytriggeringbothimmunogeniccelldeathandproliferationofregulatorytcells AT fannychalmin bleomycinexertsambivalentantitumorimmuneeffectbytriggeringbothimmunogeniccelldeathandproliferationofregulatorytcells AT frederiquevegran bleomycinexertsambivalentantitumorimmuneeffectbytriggeringbothimmunogeniccelldeathandproliferationofregulatorytcells AT cedricrebe bleomycinexertsambivalentantitumorimmuneeffectbytriggeringbothimmunogeniccelldeathandproliferationofregulatorytcells AT lionelapetoh bleomycinexertsambivalentantitumorimmuneeffectbytriggeringbothimmunogeniccelldeathandproliferationofregulatorytcells AT francoisghiringhelli bleomycinexertsambivalentantitumorimmuneeffectbytriggeringbothimmunogeniccelldeathandproliferationofregulatorytcells AT gregoiremignot bleomycinexertsambivalentantitumorimmuneeffectbytriggeringbothimmunogeniccelldeathandproliferationofregulatorytcells |
| _version_ |
1718423109724274688 |